Mode
Text Size
Log in / Sign up

Network meta-analysis of sodium bicarbonate, cholecalciferol, and protein supplementation in 2,879 chronic kidney disease patientsSodium bicarbonate, vitamin D, and protein may help chronic kidney disease patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider cholecalciferol for muscle mass and sodium bicarbonate for albumin in CKD, noting study limitations.

This systematic review and network meta-analysis included 2,879 patients with chronic kidney disease from 22 studies to assess the effects of sodium bicarbonate, cholecalciferol, and protein supplementation on muscle mass and metabolic disturbances. The analysis ranked interventions based on their probability of being the best treatment for specific outcomes.

For increasing muscle mass, cholecalciferol was advantageous with a standardized mean difference of 0.68, though the 95% confidence interval ranged from 0.09 to 1.27. Sodium bicarbonate performed better for improving serum albumin, with a standardized mean difference of 0.50 and a 95% CI of 0.01 to 0.99. Protein supplementation ranked highest for reducing serum phosphorus, indicated by a SUCRA value of 64.9%.

Regarding safety, protein supplementation ranked highest for reducing the incidence of adverse events with a SUCRA value of 71.9%. The analysis suggested sodium bicarbonate may be more effective for improving bicarbonate and potassium levels in the early stage and may have certain effects on eGFR and systolic blood pressure at 24 months.

However, substantial heterogeneity in intervention protocols and small sample sizes limit the certainty of these findings. No significant differences were observed among the three interventions for muscle mass or serum metabolic parameters overall. These associations require further validation in future large-scale, rigorously designed randomized controlled trials before clinical application.

Researchers combined results from 22 studies involving 2,879 patients with chronic kidney disease. They looked at how sodium bicarbonate, cholecalciferol (vitamin D), and protein supplementation affected muscle mass and metabolic markers. The analysis found that vitamin D was linked to better muscle mass, sodium bicarbonate was linked to higher serum albumin, and protein was linked to lower phosphorus levels. Some data suggested sodium bicarbonate might also help with blood pressure and kidney function over time.

Despite these potential benefits, the study noted that no significant differences were seen when comparing all three treatments for muscle mass or overall metabolic parameters together. Safety data indicated that protein supplementation was associated with fewer adverse events in the reviewed studies. However, the researchers did not report any serious side effects or reasons for patients stopping treatment in this specific analysis.

Readers should be cautious because the number of included studies was limited, and the sample sizes for individual treatments were small. The different ways treatments were given created substantial differences between studies. These findings are based on associations rather than proven causes. Future large-scale, rigorously designed randomized controlled trials are needed to validate these conclusions before they can change medical practice.

What this means for you:
Review suggests vitamin D, sodium bicarbonate, and protein may help specific markers in chronic kidney disease, but more research is needed.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundPatients with chronic kidney disease (CKD) often experience a decline in muscle mass and metabolic disturbances, which may increase the risk of cardiovascular events and all-cause mortality. Sodium bicarbonate, cholecalciferol, and protein supplementation are commonly used pharmacological and nutritional interventions; however, systematic evidence comparing their effects on muscle mass, metabolic status, and related outcomes in CKD patients remains lacking.MethodsWe systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from inception to July 1, 2025, and included eligible comparative clinical studies. Conventional meta-analysis and network meta-analysis (NMA) were used to compare the three categories of interventions in outcomes such as muscle mass, muscle function, and serum metabolic parameters, and surface under the cumulative ranking curve (SUCRA) values were used to rank intervention effects.ResultsA total of 22 studies involving 2,879 patients were included, comprising 11 on sodium bicarbonate, 5 on cholecalciferol, and 6 on protein supplementation. Conventional meta-analysis indicated that sodium bicarbonate may be more effective in improving HCO₃− and potassium levels in the early stage and may have certain effects on eGFR and systolic blood pressure at 24 months. NMA results showed that cholecalciferol was advantageous in increasing muscle mass (SMD = 0.68, 95% CI = 0.09 to 1.27), sodium bicarbonate performed better in improving serum albumin (SMD = 0.50, 95% CI = 0.01 to 0.99), and protein supplementation ranked highest for reducing serum phosphorus (SUCRA = 64.9%) and the incidence of adverse events (SUCRA = 71.9%). However, no significant differences were observed among the three interventions in muscle mass or serum metabolic parameters.ConclusionSodium bicarbonate and cholecalciferol may have potential advantages in improving serum albumin and increasing muscle mass, respectively. While protein supplementation may offer some value in reducing serum phosphorus and the incidence of adverse events. Given the limited number of included studies, small sample sizes, and substantial heterogeneity in intervention protocols, these conclusions should be further validated in future large-scale, rigorously designed randomized controlled trials.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251126837, identifier PROSPERO (CRD420251126837).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.